NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.

“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.

The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.

Phase-1’s founder Spencer Farr will head the company’s R&D division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.